Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Income Loss From Continuing Operations

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Icahn Enterprises's pharma — income loss from continuing operations?
Icahn Enterprises (IEP) reported pharma — income loss from continuing operations of -$7M in Q1 2026.
How has Icahn Enterprises's pharma — income loss from continuing operations changed year-over-year?
Icahn Enterprises's pharma — income loss from continuing operations decreased by 250.0% year-over-year, from -$2M to -$7M.
What is the long-term trend for Icahn Enterprises's pharma — income loss from continuing operations?
Over 3 years (2021 to 2025), Icahn Enterprises's pharma — income loss from continuing operations has grown at a 10.1% compound annual growth rate (CAGR), from -$3M to -$4M.
What does pharma — income loss from continuing operations mean?
Indicates the net financial result of the Pharma segment's primary business activities, excluding discontinued operations. This figure serves as a primary benchmark for the segment's recurring profitability and operational success. Investors use this to evaluate the sustainability and growth potential of the segment's core business model.